News
Vigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024 Vigil Neuroscience, Inc. Wed, Mar 6, 2024, 4:25 PM 4 min read ...
Azafaros Announces Key Scientific Oral and Poster Presentations on Nizubaglustat Accepted for WORLDSymposium™ 2025.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback